NCT06034821
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
Enrolling by Invitation
PHASE4Ages 18–90InterventionalTreatmentBrigham and Women's HospitalInvestigator-initiated
~1,500 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Subanesthetic dose intravenous ketamine (KET)Electroconvulsive therapy (ECT)
At a glance
Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Scale for Suicidal Ideation (SSI)
Measured over Six weeks
Conditions
Where it's being run
10 sites across 9 statesMassachusetts2
California1
Maryland1
New York1
Ohio1
Pennsylvania1
Texas1
Utah1
Study leadership
- Amit Anand, MD · PRINCIPAL_INVESTIGATOR · Brigham and Woman's Hospital, Harvard Medical School
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Scale for Suicidal Ideation (SSI)Six weeks
The Scale for Suicidal Ideation (SSI is excellent in terms of test construction and psychometrics (validity and reliability). It has been shown that a SSI score \>6 has been found to be predictive of suicide within 6 months of discharge from hospital. At the end of treatment, patients will be assessed for remission of suicidality which is defined as a SSI score \<4 i.e. no clinically significant suicidal ideation70. A stringent criterion for remission was chosen as ASD is a life-threatening illness and full remission should be the treatment goal.